|
|
| RAC September 17, 2003 - Presentation Materials |
|
| 92th Meeting Day |
| Bethesda, Maryland |
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
Discussion of Human Gene Transfer Protocol #0307-594 |
|
|
| |
A Phase I Study to Determine the Safety and Biological Activity of Cell-Mediated Gene Therapy Using Tissue Gene-C in Patients with Degenerative Joint Disease of the Knee Prior to Total Knee Arthroplasty |
|
|
| |
Michael A. Mont, M.D., Sinai Hospital, Baltimore, MD |
|
|
| |
Slides
|
|
|
| |
Robert H. Carter, M.D., University of Alabama, Birmingham |
|
|
| |
Slides
|
|
| |
|
|
|
|
Discussion of Human Gene Transfer Protocol #0307-588 |
|
|
| |
A Phase I Dose- Escalation Study of Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector containing the TNFR: Fc Fusion Gene in Rheumatoid Arthritis |
|
|
| |
Philip J. Mease, M.D., Swedish Hospital, Seattle, WA |
|
|
| |
Slides
|
|
|
| |
Robert H. Carter, M.D., University of Alabama, Birmingham |
|
|
| |
Review Slides
|
|
|
| |
Christopher H. Evans, D.Sc., Ph.D., Harvard Medical School |
|
|
| |
Review Slides
|
|
| |
|
|
|
ADJOURN |
|
| |
|
Top of Page |
| |
|
|
|
|
